SANES

10.67

+1.75%↑

BBVA

18.97

+2.46%↑

CABK

+0.32%↑

INGA

25.855

+3.01%↑

NDA.FI

15.87

+0.13%↑

SANES

10.67

+1.75%↑

BBVA

18.97

+2.46%↑

CABK

+0.32%↑

INGA

25.855

+3.01%↑

NDA.FI

15.87

+0.13%↑

SANES

10.67

+1.75%↑

BBVA

18.97

+2.46%↑

CABK

+0.32%↑

INGA

25.855

+3.01%↑

NDA.FI

15.87

+0.13%↑

SANES

10.67

+1.75%↑

BBVA

18.97

+2.46%↑

CABK

+0.32%↑

INGA

25.855

+3.01%↑

NDA.FI

15.87

+0.13%↑

SANES

10.67

+1.75%↑

BBVA

18.97

+2.46%↑

CABK

+0.32%↑

INGA

25.855

+3.01%↑

NDA.FI

15.87

+0.13%↑

Home・Elenco Azioni・Sartorius Stedim Biotech.

Sartorius Stedim Biotech.

Aperta

SettoreFinanza

166.55 -0.51

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

164.75

Massimo

169.5

Metriche Chiave
By Trading Economics
Entrata	41M 88M
Vendite	-11M 762M
P/E Media del settore	56.752 57.018
EPS	1.17
Margine di Profitto	11.569
Dipendenti	10,456
EBITDA	26M 225M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+43.47% upside

Dividendi
By Dow Jones
Utili prossimi	23 lug 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-3B 15B
Apertura precedente	167.06
Chiusura precedente	166.55

Notizie sul Sentiment di mercato

By Acuity

14%

86%

16 / 439 Classifica in Finance

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

202.7 / 211.7 Supporto e resistenza

Sartorius Stedim Biotech. Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

6 mag 2026, 23:41 UTC

Utili

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6 mag 2026, 21:40 UTC

Utili

Nutrien Logs Higher Profit, Sales Growth in 1Q

6 mag 2026, 23:47 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6 mag 2026, 23:34 UTC

Discorsi di Mercato

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6 mag 2026, 23:13 UTC

Utili

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6 mag 2026, 23:13 UTC

Utili

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6 mag 2026, 23:12 UTC

Utili

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6 mag 2026, 23:11 UTC

Utili

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6 mag 2026, 23:11 UTC

Utili

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6 mag 2026, 23:11 UTC

Utili

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6 mag 2026, 23:11 UTC

Utili

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6 mag 2026, 23:11 UTC

Utili

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6 mag 2026, 23:11 UTC

Utili

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6 mag 2026, 23:07 UTC

Utili

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6 mag 2026, 23:06 UTC

Utili

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6 mag 2026, 23:06 UTC

Utili

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6 mag 2026, 23:05 UTC

Utili

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6 mag 2026, 23:04 UTC

Utili

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6 mag 2026, 22:50 UTC

Utili

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6 mag 2026, 22:25 UTC

Discorsi di Mercato

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6 mag 2026, 22:11 UTC

Utili

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6 mag 2026, 22:11 UTC

Utili

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6 mag 2026, 22:05 UTC

Discorsi di Mercato

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6 mag 2026, 21:58 UTC

Utili

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mag 2026, 21:47 UTC

Discorsi di Mercato

Utili

Costco Posts 13% Sales Growth in April -- Market Talk

6 mag 2026, 21:46 UTC

Utili

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6 mag 2026, 21:40 UTC

Utili

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mag 2026, 21:35 UTC

Discorsi di Mercato

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6 mag 2026, 21:32 UTC

Azioni calde

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6 mag 2026, 21:29 UTC

Utili

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Sartorius Stedim Biotech. Previsione

Obiettivo di Prezzo

By TipRanks

43.47% in crescita

Previsioni per 12 mesi

Media 233 EUR 43.47%

Alto 262 EUR

Basso 210 EUR

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sartorius Stedim Biotech. - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 8 che hanno fornito valutazioni azionarie a Sartorius Stedim Biotech. - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

202.7 / 211.7Supporto e resistenza

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

16 / 439 Classifica in Finanza

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.